Biotech investors love “pipeline value,” but most portfolio rankings still miss the point.
The real question isn’t which programs are most promising on paper—it’s which ones are most likely to create risk-adjusted, investable returns given the brutal e…

Biopharma’s “patent cliff” isn’t just a pricing story—it’s a talent story.
Most people talk about the cliff in terms of revenue: when exclusivity ends, generic and biosimilar competition arrives, margins compress, and pipelines get scrutinized. But t…

Stop Overstocking. Start Seeing Patent Risk.
Branded drug inventory is supposed to be predictable—until it isn’t.
One day, your wholesaler network is moving product smoothly. The next, a patent cliff hits, a generic competitor launches, and suddenly th…

Big Pharma has a hiring “tell” that most people miss.
It’s not a job posting. It’s not a press release. It’s the patent cliff.
When blockbuster exclusivity starts to expire, companies don’t just lose revenue—they lose certainty. And that uncertainty sh…

Biosimilar sourcing isn’t a procurement problem—it’s a patent strategy problem.
If you’re planning a switch from an originator biologic to a biosimilar, the hardest part usually isn’t identifying candidates. It’s timing. It’s sequencing. It’s making su…

Pharma has a familiar playbook: take an old drug, reframe it as “new,” and then price it like it’s never been seen before.
That’s the tension at the heart of the latest discussion from DrugPatentWatch—how companies justify premium pricing for repurpose…

Pharma recruiters don’t just “find talent.” They find signal.
In a market where everyone claims to be “innovative,” the fastest way to separate real scientific depth from polished resumes is to look at what scientists actually cite—especially in patent…

Pharma has a playbook for “new” pricing that doesn’t require new molecules.
In a world where investors want growth and payers want predictability, the industry has found a way to reframe repurposed medicines as premium innovations—often without the kin…

Pharma has a new playbook—and it’s not always about new science.
In a world where “innovation” is the currency of premium pricing, drugmakers increasingly justify higher costs for repurposed medicines using a familiar narrative: same molecule, new valu…

Russia’s “Third-Wheel” Rule Isn’t Just Bureaucracy—It’s a Signal for API and Full-Cycle Drug Power
In the world of pharma, the loudest headlines are often about approvals, pricing, and shortages. But the real story is frequently written in the margins—…